Concerning fatty acid oxidation, increased β-oxidation is a source of ROS and the protective mechanism of PPAR α agonists in NAFLD should thus be associated with enhanced anti-oxidant capacity31. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.